Skip to main content
. 2018 Apr 14;8(10):2799–2813. doi: 10.7150/thno.22980

Figure 3.

Figure 3

177Lu-DOTATATE selectively killed hSSTr2+ teratomas as demonstrated by small-animal PET and macroscopic tumor measurements. Representative small-animal PET images after intravenous administration of 68Ga-DOTATATE before and 27 days after intravenous saline (A) or 177Lu-DOTATATE (B) injection. (C) Relative total lesion uptake of hSSTr2+ teratomas, i.e., the total lesion uptake of 68Ga-DOTATATE divided by the total lesion uptake before saline or 177Lu-DOTATATE injection, demonstrated a significant decrease in animals injected with 177Lu-DOTATATE (n=10) compared to saline-injected animals (n=7) (****p<0.0001). Representative small-animal PET images after intravenous administration of 124I- before and 28 days after intravenous saline (D) or 177Lu-DOTATATE (E) injection. (F) Relative total lesion uptake of hNIS+ teratomas demonstrated no difference between animals injected with saline (n=4) or with 177Lu-DOTATATE (n=4). (G) hSSTr2+ teratoma volumes significantly decreased upon exposure to 177Lu-DOTATATE compared to saline-treated groups (*p<0.05; **p<0.01). (H) No difference in teratoma volumes was observed between hNIS-expressing teratomas exposed to either saline or 177Lu-DOTATATE.